Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
Abstract The progestin-based hormonal contraceptive Depot Medroxyprogesterone Acetate (DMPA) is widely used in sub-Saharan Africa, where HIV-1 is endemic. Meta-analyses have shown that women using DMPA are 40% more likely than women not using hormonal contraceptives to acquire Human Immunodeficiency...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-02-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-83242-9 |
id |
doaj-2c3623001ed1450a83368b237c5f59e6 |
---|---|
record_format |
Article |
spelling |
doaj-2c3623001ed1450a83368b237c5f59e62021-02-21T12:33:23ZengNature Publishing GroupScientific Reports2045-23222021-02-0111111610.1038/s41598-021-83242-9Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized miceJocelyn M. Wessels0Philip V. Nguyen1Danielle Vitali2Kristen Mueller3Fatemeh Vahedi4Allison M. Felker5Haley A. Dupont6Puja Bagri7Chris P. Verschoor8Alexandre Deshiere9Tony Mazzulli10Michel J. Tremblay11Ali A. Ashkar12Charu Kaushic13McMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityDepartment of Pathology and Molecular Medicine, McMaster UniversityAxe Des Maladies Infectieuses Et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Pavillon CHULPublic Health Laboratories, Public Health OntarioAxe Des Maladies Infectieuses Et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Pavillon CHULMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityAbstract The progestin-based hormonal contraceptive Depot Medroxyprogesterone Acetate (DMPA) is widely used in sub-Saharan Africa, where HIV-1 is endemic. Meta-analyses have shown that women using DMPA are 40% more likely than women not using hormonal contraceptives to acquire Human Immunodeficiency Virus (HIV-1). Therefore understanding how DMPA increases susceptibility to HIV-1 is an important public health issue. Using C57BL/6 mice and our previously optimized humanized mouse model (NOD-Rag1 tm1Mom Il2rg tm1Wjl transplanted with hCD34-enriched hematopoietic stem cells; Hu-mice) where peripheral blood and tissues are reconstituted by human immune cells, we assessed how DMPA affected mucosal barrier function, HIV-1 susceptibility, viral titres, and target cells compared to mice in the diestrus phase of the estrous cycle, when endogenous progesterone is highest. We found that DMPA enhanced FITC-dextran dye leakage from the vaginal tract into the systemic circulation, enhanced target cells (hCD68+ macrophages, hCD4+ T cells) in the vaginal tract and peripheral blood (hCD45+hCD3+hCD4+hCCR5+ T cells), increased the rate of intravaginal HIV-1 infection, extended the window of vulnerability, and lowered vaginal viral titres following infection. These findings suggest DMPA may enhance susceptibility to HIV-1 in Hu-mice by impairing the vaginal epithelial barrier, increasing vaginal target cells (including macrophages), and extending the period of time during which Hu-mice are susceptible to infection; mechanisms that might also affect HIV-1 susceptibility in women.https://doi.org/10.1038/s41598-021-83242-9 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jocelyn M. Wessels Philip V. Nguyen Danielle Vitali Kristen Mueller Fatemeh Vahedi Allison M. Felker Haley A. Dupont Puja Bagri Chris P. Verschoor Alexandre Deshiere Tony Mazzulli Michel J. Tremblay Ali A. Ashkar Charu Kaushic |
spellingShingle |
Jocelyn M. Wessels Philip V. Nguyen Danielle Vitali Kristen Mueller Fatemeh Vahedi Allison M. Felker Haley A. Dupont Puja Bagri Chris P. Verschoor Alexandre Deshiere Tony Mazzulli Michel J. Tremblay Ali A. Ashkar Charu Kaushic Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice Scientific Reports |
author_facet |
Jocelyn M. Wessels Philip V. Nguyen Danielle Vitali Kristen Mueller Fatemeh Vahedi Allison M. Felker Haley A. Dupont Puja Bagri Chris P. Verschoor Alexandre Deshiere Tony Mazzulli Michel J. Tremblay Ali A. Ashkar Charu Kaushic |
author_sort |
Jocelyn M. Wessels |
title |
Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice |
title_short |
Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice |
title_full |
Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice |
title_fullStr |
Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice |
title_full_unstemmed |
Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice |
title_sort |
depot medroxyprogesterone acetate (dmpa) enhances susceptibility and increases the window of vulnerability to hiv-1 in humanized mice |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-02-01 |
description |
Abstract The progestin-based hormonal contraceptive Depot Medroxyprogesterone Acetate (DMPA) is widely used in sub-Saharan Africa, where HIV-1 is endemic. Meta-analyses have shown that women using DMPA are 40% more likely than women not using hormonal contraceptives to acquire Human Immunodeficiency Virus (HIV-1). Therefore understanding how DMPA increases susceptibility to HIV-1 is an important public health issue. Using C57BL/6 mice and our previously optimized humanized mouse model (NOD-Rag1 tm1Mom Il2rg tm1Wjl transplanted with hCD34-enriched hematopoietic stem cells; Hu-mice) where peripheral blood and tissues are reconstituted by human immune cells, we assessed how DMPA affected mucosal barrier function, HIV-1 susceptibility, viral titres, and target cells compared to mice in the diestrus phase of the estrous cycle, when endogenous progesterone is highest. We found that DMPA enhanced FITC-dextran dye leakage from the vaginal tract into the systemic circulation, enhanced target cells (hCD68+ macrophages, hCD4+ T cells) in the vaginal tract and peripheral blood (hCD45+hCD3+hCD4+hCCR5+ T cells), increased the rate of intravaginal HIV-1 infection, extended the window of vulnerability, and lowered vaginal viral titres following infection. These findings suggest DMPA may enhance susceptibility to HIV-1 in Hu-mice by impairing the vaginal epithelial barrier, increasing vaginal target cells (including macrophages), and extending the period of time during which Hu-mice are susceptible to infection; mechanisms that might also affect HIV-1 susceptibility in women. |
url |
https://doi.org/10.1038/s41598-021-83242-9 |
work_keys_str_mv |
AT jocelynmwessels depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT philipvnguyen depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT daniellevitali depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT kristenmueller depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT fatemehvahedi depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT allisonmfelker depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT haleyadupont depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT pujabagri depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT chrispverschoor depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT alexandredeshiere depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT tonymazzulli depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT micheljtremblay depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT aliaashkar depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice AT charukaushic depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice |
_version_ |
1724257898063724544 |